Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Common-Size Balance Sheet: Assets

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Gilead Sciences Inc., common-size consolidated balance sheet: assets

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents
Short-term marketable debt securities
Accounts receivable, net
Inventories
Prepaid and other current assets
Current assets
Property, plant and equipment, net
Long-term marketable debt securities
Intangible assets, net
Goodwill
Other long-term assets
Long-term assets
Total assets

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Gilead Sciences Inc. current assets as a percentage of total assets increased from 2021 to 2022 and from 2022 to 2023.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Gilead Sciences Inc. property, plant and equipment, net as a percentage of total assets increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Gilead Sciences Inc. long-term assets as a percentage of total assets decreased from 2021 to 2022 and from 2022 to 2023.